 |
Joint
Care eNews #2 / April 2005 |
| Joint Care Headlines | ||||
| In
2004 Bioiberica consolidated its leadership in joint
health. With a 14% increase in sales compared to 2003 and very good prospects for 2005, Bioiberica closed fiscal year 2004 with great optimism. (more) A positioning study reflects market perceptions of Bioiberica. The market survey has concluded that Bioiberica's positioning is based on quality, science and technology, whereas some of its competitors are positioned in customer service and low prices. (more) 1 out of every 4 Spanish patients treated with chondroprotectors uses a product from Bioiberica. In the last two years, the market of chondroprotective Rx drugs in Spain has grown considerably. In 2004, the number of patients with osteoarthritis treated with chondroprotectors increased by 32%. (more) |
||||
|
| ||||
| Joint Care News | ||||
| In 2004 Bioiberica consolidated its leadership in joint
health. With a 14% increase in sales compared to 2003 and very good prospects for 2005, Bioiberica closed fiscal year 2004 with great optimism. Bioiberica's presence on new markets such as those in Eastern Europe and South America, the launch of new products such as Hyal-Joint and the increase in our market share in the countries where Bioiberica has been operating for some time, especially the pharmaceuticals market, have consolidated the company's leadership in joint health. Bioiberica's good results have not only been evident in terms of sales, but also in scientific research. In 2004, Bioiberica stepped up its efforts in the area of R&D, hired four new people in this area and increased its spending by 40% compared to 2003. It also continued to be the leading researcher of chondroprotection at the clinical and preclinical levels, with 11 articles published in the world's most renowned scientific journals. (top) A positioning study reflects market perceptions of Bioiberica. The market survey has concluded that Bioiberica's positioning is based on quality, science and technology, whereas some of its competitors are positioned in customer service and low prices. This qualitative market research, designed to find out about the image and positioning of Bioiberica and its competitors, was carried out by a US market-research firm and entailed surveying executives of companies of the American market. The survey involved in-depth analysis of the attributes associated with each supplier. Bioiberica's products were always considered to be superior to the rest, i.e., they were "at the higher end," according to those surveyed. Likewise, the attributes of science and technology were considered proof of Bioiberica's leadership as a producer of active ingredients for joint-health products. These attributes were also seen as guarantees of the company's excellent credibility compared with its competitors. In summary, according to the results of the survey, Bioiberica is perceived as a pioneering company on the joint-health market that is associated with the highest quality standards and scientific approach. (top) 1 out of every 4 Spanish patients treated with chondroprotectors uses a product from Bioiberica. In the last two years, the market of chondroprotective Rx drugs in Spain has grown considerably. In 2004, the number of patients with osteoarthritis treated with chondroprotectors increased by 32%. A significant part of this growth is due to the good results obtained by the Bioiberica Farma products, which have stimulated sales of chondroprotective drugs since they were first launched, thus attracting new patients to the category. In fact, Condro.san® (Chondroitin) is the product that has attracted the most new patients to the chondroprotection market, with the contribution of about 53% of all new patients since 2004. Thus, in only two years, Bioiberica Farma has ensured that 1 out of every 4 patients treated with chondroprotectors in Spain uses a product from Bioiberica. With Condro.san® (Chondroitin), Cartisorb® (Glucosamine) and Hyalgan® (Hyaluronic Acid), Bioiberica Farma offers the broadest range of chondroprotective drugs. (top) |
||||
| Short News | ||
| VITAFOODS
2005 Like every year, BIOIBERICA will participate in VITAFOODS, the international ingredients trade fair for the nutraceuticals market. We will be pleased to receive you at Stand 116 in Hall 1, Palexpo, Geneva, Switzerland, from 10 to 12 May 2005. Vitafoods web BIOIBERICA AT THE AAOS CONGRESS Bioiberica participated with its US partner Nutramax Labs. Inc. in the congress of the American Academy of Orthopedic Surgeons (AAOS), held in Washington DC from 23 to 25 February 2005. The AAOS congress is the world's largest meeting of orthopedic surgeons and allied health professionals and presents the latest information on orthopedic treatments, advances and research. |
||
| Latest eNews | ||
| You can read previous numbers of Joint Care
eNews online at our website: Number 1 |
||
| Our Products | ||
 | ||
 |
||
 |
||
| If
you don't want to receive any further Joint Care eNews,
please click here to unsubscribe. |
Bioiberica SA follows the Spanish Organic Law 15, 13th of Dec 1999. According to the Spanish organic law of data protection we are obliged to communicate to you that any data that you may provide to us by telephone or written will remain totally confidential in the DB of Bioiberica SA and it will only be used by Bioiberica SA, until you tell us not to continue doing so. You will always have the right to modify any of your data at any time. | ||||
 |
|
||||||||